Translational Breast Cancer Research最新文献_第4页

Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review 降低乳腺癌PALB2突变携带者的手术风险:病例系列和文献综述

Translational Breast Cancer Research Pub Date : 2022-10-01 DOI: 10.21037/tbcr-22-33

Monika K Masanam, Clark W. Pitcher, Olutayo A. Sogunro, Leah K. Starks, A. Murray, M. Boisvert

引用次数: 0

A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view 圆桌讨论:曲妥珠单抗德鲁德替康治疗乳腺癌的临床前景:回顾性和前瞻性观点

Translational Breast Cancer Research Pub Date : 2022-10-01 DOI: 10.21037/tbcr-22-45

Xu Liang, Ying Yan, Guo-hong Song

{"title":"A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view","authors":"Xu Liang, Ying Yan, Guo-hong Song","doi":"10.21037/tbcr-22-45","DOIUrl":"https://doi.org/10.21037/tbcr-22-45","url":null,"abstract":": The treatment landscape of breast cancer has been greatly changed by the innovative targeting therapies. Antibody-drug conjugates (ADCs) with a representative of trastuzumab deruxtecan (T-DXd) are the most successful ones. The revolutionary next-generation design of ADC transformed to the unprecedented clinical data. The DESTINY-BREAST01 and DESTINY-BREAST03 trials have changed the standard of care for HER2-positve metastatic breast cancer (MBC). At the same time the clinical data of T-DXd in HER2-postive patients with brain metastasis (BM) is numerously gaining and challenging the current treatment concept for central nerve system (CNS) involved disease. The DESTINY-BREAST series trials have quickly expanded to first-line (1L) and early setting of breast cancer. The newly reported positive result of DESTINY-BREAST04 trial has also opening the door of human epidermal growth factor receptor 2 (HER2)-low era. The breast cancer experts are facing a world of massive data and rapidly changing. Therefore, round table discussion meeting is a great way to share the information and options of among oncologists. This time, the breast cancer experts in China gathered to discuss the important clinical advances of T-DXd and its impact to clinical practice. The meeting minutes were recorded and organized as the review article. This would provide insights to better understanding of the current data and shape the further research directions of breast cancer.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"110 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134245552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition) HER2乳腺癌临床诊断及靶向治疗专家共识(2023版)

Translational Breast Cancer Research Pub Date : 2022-10-01 DOI: 10.21037/tbcr-22-48

Jianbin Li, Xiaojian Wang, Shusen Wang, Shu Wang, Tao Wang, Yueping Liu, C. Geng, Feng Jin, Yongmei Yin, Qingyuan Zhang, Erwei Song, Jiong Wu, Zefei Jiang

引用次数: 1

CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis CSCO专家对乳腺癌脑转移诊断与治疗的共识

Translational Breast Cancer Research Pub Date : 2022-07-01 DOI: 10.21037/tbcr-22-30

Tao Wang, Jiayi Chen, Jin Yang, Minjie Fu, W. Hua, Wang Jia, Yueping Liu, Biyun Wang, M. Yan, Juan Zhou, Chun-fang Hao, Jiaxin Chen, D. Ou, Tao Jiang, Ying Mao, Zefei Jiang

引用次数: 1

A case report of gender-affirming mastectomy in a transgender individual with breast cancer 变性乳腺癌患者行性别确认乳房切除术一例报告

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-14

N. Bhagat, Lauren A. Lautenslager, I. Hadad

引用次数: 0

Breast cancer gene expression signatures: development and clinical significance—a narrative review 乳腺癌基因表达特征:发展及其临床意义

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-39

Siyan Li, Xinmiao Yu, Yingying Xu

引用次数: 0

Key points of breast cancer management under public health emergencies 突发公共卫生事件下乳腺癌管理要点

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-28

Rui Ge, Jianbin Li, Zefei Jiang

引用次数: 1

CSCO Breast Cancer Management Guidelines 2022: Australian Perspective CSCO乳腺癌管理指南2022:澳大利亚视角

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-22-46

C. Yong, Anurag Gupta, R. Joshi

引用次数: 0

Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study 内分泌治疗是激素受体阳性晚期乳腺癌的一线和二线治疗选择

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-21-49

Xiaojia Wang

{"title":"Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study","authors":"Xiaojia Wang","doi":"10.21037/tbcr-21-49","DOIUrl":"https://doi.org/10.21037/tbcr-21-49","url":null,"abstract":"Advanced/metastatic breast cancer (MBC) is the later stage in the development of breast cancer. The survival time of MBC patients is short, and palliative treatment is the main method of therapy. MBC patients are often resistant to various antitumor drugs and have a myriad of complications and visceral involvement. Therefore, these patients have a poor prognosis and little hope of being cured (1). Hormone receptor-positive (HR+) breast cancer progresses slowly and often has a good prognosis, and the vast majority of patients in whom it was detected early were cured. In the case of MBC, the patients who were HR+ mainly had nonvisceral metastasis, such as bone, regional lymph node, or local soft tissue metastasis. For patients experiencing the first recurrence of breast cancer and metastasis, a comprehensive assessment is needed prior to treatment, and this includes biopsies of metastasis lesions. This assessment helps to determine the source of the metastasis lesions and to further clarify molecular markers such as HR expression, HER-2 status, and Ki67 index. In addition, we often see that the receptor expression is various or changes between metastasis and primary lesions. These inconsistencies and heterogeneity are helpful to determine the next treatment strategy. Clinical practice has shown that the molecular markers change in nearly half of the metastasis tumors, and estrogen receptor expression decreased or became negative. In this situation, the effect of hormone therapy is poor.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129393043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovation drug approvals based on a bridging study: from concept to practice 基于桥接研究的创新药物审批:从概念到实践

Translational Breast Cancer Research Pub Date : 2022-01-01 DOI: 10.21037/tbcr-21-43

Tao Wang, Xiao Cao, Ying-jian He, Xiaoyuan Chen

引用次数: 0